07:00 , Oct 15, 2012 |  BC Week In Review  |  Company News

Sigma-Tau sales and marketing update

Sigma-Tau expanded its patient assistance program for severe combined immunodeficiency disease (SCID) drug Adagen to include a co-pay assistance program in the U.S. The program will cover 100% of any out-of-pocket patient costs associated...
08:00 , Nov 16, 2009 |  BC Week In Review  |  Company News

Enzon, Sigma-Tau S.p.A. deal

Sigma-Tau, which said the deal will increase its presence in the field of rare diseases, also will acquire Enzon's Indianapolis, Ind. manufacturing facility. Goldman Sachs and Greenhill advised Enzon. The deal is expected to close...
08:00 , Nov 16, 2009 |  BioCentury  |  Strategy

Leftovers in Enzon's refrigerator

Now that activist shareholders have won their two-year battle to restructure Enzon Pharmaceuticals Inc., the question is what will happen to the development stage assets that remain. Last week, the company announced it will sell its...
01:15 , Nov 10, 2009 |  BC Extra  |  Top Story

Enzon to sell specialty pharma business

Sigma-Tau S.p.A. (Rome, Italy) will acquire the specialty pharmaceuticals business of Enzon Pharmaceuticals Inc. (NASDAQ:ENZN) for $300 million in cash and up to $27 million in potential milestones. The deal includes four marketed products: antifungal...
08:00 , Feb 9, 2009 |  BC Week In Review  |  Company News

Enzon drug delivery, infectious, cancer news

Knott Partners, which owns about 4% of Enzon, sent a letter to CEO Jeffery Buchalter and the board suggesting immediate action, including a share buyback plan; an auction for the entire company or its specialty...
07:00 , Aug 18, 2008 |  BC Week In Review  |  Company News

Enzon drug delivery, infectious, cancer news

Enzon will explore strategic alternatives for its specialty pharmaceutical business while the company continues to pursue a plan to spin out its biotech business. Alternatives the company is considering include selling the entire specialty pharma...
01:20 , Aug 12, 2008 |  BC Extra  |  Company News

Enzon seeking alternatives for specialty pharma unit

Enzon (NASDAQ:ENZN) said it is exploring strategic alternatives for its specialty pharmaceutical business even as the company continues to pursue a plan to spin out its biotech business. The company said the alternatives it is...
07:00 , Mar 17, 2008 |  BioCentury  |  Finance

Ebb & Flow

Amgen investors were initially relieved after Thursday's votes by FDA's Oncologic Drugs Advisory Committee not to remove chemotherapy-induced anemia from the labels of erythropoiesis-stimulating agents. The stock closed the day up $2.19 to $47.18. But on...
00:40 , Mar 15, 2008 |  BC Extra  |  Financial News

Icahn urges Enzon to sell

In an SEC filing posted on Friday, financier Carl Icahn and investors associated with Icahn disclosed they have increased their holdings in Enzon (NASDAQ:ENZN) and urged the company to consider alternatives including a sale. The...
01:27 , May 19, 2006 |  BC Extra  |  Financial News

Enzon raises $225M in note deal

ENZN raised $225 million in a bumped-up placement of convertible senior notes due in 2013. On Tuesday, the company proposed to raise up to $175 million in the deal. The notes bear 4% interest and...